Literature DB >> 12432234

Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects.

Wen-Fang Cheng1, Chien-Fu Hung, Sara I Pai, Keng-Fu Hsu, Liangmei He, Morris Ling, T-C Wu.   

Abstract

The use of DNA vaccines for generating antigen-specific CD8+ T cell responses has been well established. However, little is known about the quantitative and qualitative aspects of CD8+ T cell responses and protective immunity generated after repeated DNA vaccinations. We used human papillomavirus (HPV) type-16 E7 as a model tumor antigen in an E7-expressing tumor model, TC-1, to assess the influence of the frequency of DNA vaccinations on E7-specific immunological and antitumor responses. Mice were vaccinated with 1-4 inoculations of pcDNA 3-E7 DNA. Immunological assays and tumor protection experiments were performed to assess the effect of repeated E7 DNA vaccination on E7-specific T cells and E7-expressing tumors. Our results demonstrated that mice receiving an increased number of E7 DNA vaccinations exhibited higher E7-specific CTL activity, a rapid expansion of E7-specific IFN-gamma-secreting CD8+ T cells upon stimulation with E7 antigen, and a stronger antitumor effect against an E7-expressing tumor. Furthermore, we found that increasing the number of E7 DNA vaccinations followed by vaccinia booster enhanced the functional avidity of E7-specific CD8+ T cells. Our data suggest that quantitative and qualitative characteristics of antigen-specific CD8 + T cell responses and the ensuing protective antitumor effect can be influenced by the frequency of DNA vaccinations. These results have important clinical implications for the use of naked DNA vaccines in cancer immunotherapy. Copyright 2002 National Science Council, ROC and S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12432234     DOI: 10.1159/000067285

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  7 in total

Review 1.  Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009 - present).

Authors:  Kristin Landis-Piwowar; Di Chen; Robert Foldes; Tak-Hang Chan; Qing Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2012-12-12       Impact factor: 6.674

2.  Metronomic chemotherapy enhances antitumor effects of cancer vaccine by depleting regulatory T lymphocytes and inhibiting tumor angiogenesis.

Authors:  Chi-An Chen; Chih-Ming Ho; Ming-Cheng Chang; Wei-Zun Sun; Yu-Li Chen; Ying-Cheng Chiang; Ming-Hong Syu; Chang-Yao Hsieh; Wen-Fang Cheng
Journal:  Mol Ther       Date:  2010-04-06       Impact factor: 11.454

3.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.

Authors:  Jian Yan; Kristina Harris; Amir S Khan; Ruxandra Draghia-Akli; Duane Sewell; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

4.  Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.

Authors:  Yong Sung Park; Jin Hyup Lee; Chien-Fu Hung; T-C Wu; Tae Woo Kim
Journal:  Infect Immun       Date:  2008-02-19       Impact factor: 3.441

5.  Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.

Authors:  Janet L Brandsma; Mark Shlyankevich; Yuhua Su; Daniel Zelterman; John K Rose; Linda Buonocore
Journal:  Vaccine       Date:  2009-07-15       Impact factor: 3.641

6.  The development of a novel cancer immunotherapeutic platform using tumor-targeting mesenchymal stem cells and a protein vaccine.

Authors:  Hon-Jian Wei; Alexander T H Wu; Chung-Huei Hsu; Yi-Ping Lin; Wen-Fang Cheng; Ching-Hua Su; Wen-Ta Chiu; Jacqueline Whang-Peng; Frank L Douglas; Win-Ping Deng
Journal:  Mol Ther       Date:  2011-07-26       Impact factor: 12.910

7.  A comprehensive in silico analysis for identification of therapeutic epitopes in HPV16, 18, 31 and 45 oncoproteins.

Authors:  Heidar Ali Panahi; Azam Bolhassani; Gholamreza Javadi; Zahra Noormohammadi
Journal:  PLoS One       Date:  2018-10-24       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.